TW200724142A - Novel compounds - Google Patents

Novel compounds

Info

Publication number: TW200724142A
Authority: TW; Taiwan
Prior art keywords: novel compounds; compounds; csbp; pyrimido; trisubstituted
Prior art date: 2005-03-25

Application number

TW095109982A

Other languages

English (en)

Inventor

James Francis Callahan

Ze-Hong Wan

hong-xing Yan

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-25

Filing date

2006-03-23

Publication date

2007-07-01

2006-03-23 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2007-07-01 Publication of TW200724142A publication Critical patent/TW200724142A/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Diabetes (AREA)
Neurology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Dermatology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Endocrinology (AREA)

TW095109982A 2005-03-25 2006-03-23 Novel compounds TW200724142A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US66534705P	2005-03-25	2005-03-25

Publications (1)

Publication Number	Publication Date
TW200724142A true TW200724142A (en)	2007-07-01

Family

ID=37053936

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095109982A TW200724142A (en)	2005-03-25	2006-03-23	Novel compounds

Country Status (23)

Country	Link
US (4)	US20090239846A1 (zh)
EP (1)	EP1866311A4 (zh)
JP (1)	JP2008535820A (zh)
KR (1)	KR20080005223A (zh)
CN (1)	CN101184758B (zh)
AP (1)	AP2281A (zh)
AR (1)	AR053450A1 (zh)
AU (1)	AU2006229967B2 (zh)
BR (1)	BRPI0609579A2 (zh)
CA (1)	CA2602546A1 (zh)
EA (1)	EA200702074A1 (zh)
IL (1)	IL185915A0 (zh)
MA (1)	MA29340B1 (zh)
MX (1)	MX2007011883A (zh)
NO (1)	NO20075273L (zh)
NZ (1)	NZ561438A (zh)
PE (2)	PE20100741A1 (zh)
SG (1)	SG166100A1 (zh)
TW (1)	TW200724142A (zh)
UA (1)	UA95230C2 (zh)
UY (1)	UY29439A1 (zh)
WO (1)	WO2006104889A2 (zh)
ZA (1)	ZA200707798B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235551B2 (en) *	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CA2426654C (en)	2000-10-23	2010-12-21	Smithkline Beecham Corporation	2,4,8-trisubstituted-8h-pyrido[2,3-d}pyrimidin-7-one compounds
EP2258687B1 (en)	2002-02-12	2012-12-26	Glaxosmithkline LLC	Nicotinamide derivates useful as P38 inhibitors
PL373339A1 (en) *	2002-04-19	2005-08-22	Smithkline Beecham Corporation	Novel compounds
US20080096905A1 (en) *	2005-03-25	2008-04-24	Glaxo Group Limited	Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
UY29439A1 (es) *	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
TWI389690B (zh)	2005-03-25	2013-03-21	Glaxo Group Ltd	新穎化合物（一）
US20090137550A1 (en) *	2005-03-25	2009-05-28	Glaxo Group Limited	Novel Compounds
WO2007147104A2 (en) *	2006-06-16	2007-12-21	Glaxo Group Limited	Novel compounds
US20090318424A1 (en) *	2006-06-16	2009-12-24	Mauro Corsi	Novel compounds
JP2009542816A (ja) *	2006-06-16	2009-12-03	グラクソグループリミテッド	新規化合物
CN101605760B (zh) *	2007-02-09	2012-06-20	陶氏益农公司	将某些取代的硫亚胺氧化为杀虫性磺基肟的方法
EP1992344A1 (en)	2007-05-18	2008-11-19	Institut Curie	P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
MX2010013559A (es) *	2008-06-11	2011-05-19	Irm Llc	Compuestos y composiciones utiles para el tratamiento de malaria.
CN103827118B (zh) *	2011-07-27	2016-03-09	葛兰素集团有限公司	双环嘧啶酮化合物
LT3691620T (lt)	2017-10-05	2022-09-26	Fulcrum Therapeutics, Inc.	P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN111961034A (zh) *	2019-05-20	2020-11-20	浙江同源康医药股份有限公司	用作ret激酶抑制剂的化合物及其应用
CN113750095B (zh) *	2021-03-10	2023-07-04	中国医学科学院医药生物技术研究所	含有环丙基骨架的化合物在制备治疗和/或预防冠状病毒感染药物中的应用

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA966134A (en) *	1972-05-05	1975-04-15	Haydn W.R. Williams	1,8-naphthyridine compounds
JPS5618982A (en) *	1979-06-14	1981-02-23	Wellcome Found	Pyrimidine derivatives and medicinal drug containing them
GB2064336B (en)	1979-12-06	1984-03-14	Glaxo Group Ltd	Device for dispensing medicaments
US4353656A (en)	1980-10-14	1982-10-12	Xerox Corporation	Moving coil, multiple energy print hammer system including a closed loop servo
EP0069715B1 (en)	1981-07-08	1986-11-05	Aktiebolaget Draco	Powder inhalator
GB2123831B (en)	1981-07-20	1986-01-15	Ciba Geigy Ag	Trisubstituted oxazo compounds
FI79651C (fi)	1982-10-08	1990-02-12	Glaxo Group Ltd	Doseringsanordning foer medicin.
US4778054A (en)	1982-10-08	1988-10-18	Glaxo Group Limited	Pack for administering medicaments to patients
GB2169265B (en)	1982-10-08	1987-08-12	Glaxo Group Ltd	Pack for medicament
JPS60226882A (ja) *	1984-04-24	1985-11-12	Nippon Zoki Pharmaceut Co Ltd	新規ピリミドピリミジン誘導体
US4560691A (en) *	1984-07-13	1985-12-24	Sterling Drug Inc.	5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and preparation
IL79550A (en)	1985-07-30	1991-06-10	Glaxo Group Ltd	Devices for administering medicaments to patients
AU598093B2 (en)	1987-02-07	1990-06-14	Wellcome Foundation Limited, The	Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
JPH01261306A (ja)	1988-04-13	1989-10-18	Nippon Kayaku Co Ltd	２−アルキルチオ−４−アミノピリミジン誘導体を有効成分とする開花促進剤
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
IE913473A1 (en) *	1990-10-15	1992-04-22	Fujisawa Pharmaceutical Co	Quinazoline derivatives and their preparation
JPH06502178A (ja)	1990-12-31	1994-03-10	藤沢薬品工業株式会社	イミダゾトリアジン誘導体
ATE159009T1 (de) *	1991-05-10	1997-10-15	Rhone Poulenc Rorer Int	Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
IL102764A0 (en)	1991-08-16	1993-01-31	Merck & Co Inc	Quinazoline derivatives,and pharmaceutical compositions containing them
DE4131029A1 (de) *	1991-09-18	1993-07-29	Basf Ag	Substituierte pyrido (2,3-d) pyrimidine als antidots
GB9127376D0 (en)	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
GB9303993D0 (en)	1993-02-26	1993-04-14	Fujisawa Pharmaceutical Co	New heterocyclic derivatives
US5466692A (en) *	1993-03-24	1995-11-14	American Home Products Corporation	Substituted pyridopyrimidines and antihypertensives
US5426110A (en) *	1993-10-06	1995-06-20	Eli Lilly And Company	Pyrimidinyl-glutamic acid derivatives
GB9325217D0 (en)	1993-12-09	1994-02-09	Zeneca Ltd	Pyrimidine derivatives
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5547954A (en) *	1994-05-26	1996-08-20	Fmc Corporation	2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
TW574214B (en)	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
EP0765308B1 (en)	1994-06-15	2000-04-05	The Wellcome Foundation Limited	Enzyme inhibitors
AU3265695A (en) *	1994-08-29	1996-03-22	Yamanouchi Pharmaceutical Co., Ltd.	Novel naphthyridine derivative and medicinal composition thereof
IL115256A0 (en) *	1994-11-14	1995-12-31	Warner Lambert Co	6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
AU698364B2 (en)	1995-03-10	1998-10-29	Minnesota Mining And Manufacturing Company	Aerosol valves
US5620981A (en) *	1995-05-03	1997-04-15	Warner-Lambert Company	Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US5760220A (en) *	1995-06-07	1998-06-02	American Home Products Corporation	Process for preparation of biphenyl derivatives
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
AU2521597A (en)	1996-04-12	1997-11-07	Sumitomo Pharmaceuticals Company, Limited	Piperidinylpyramidine derivatives
US6875769B2 (en) *	1996-05-23	2005-04-05	Pfizer Inc.	Substituted6,6-hetero-bicyclicderivatives
ZA973884B (en) *	1996-05-23	1998-11-06	Du Pont Merck Pharma	Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US6492520B1 (en)	1996-08-06	2002-12-10	Pfizer Inc	Substituted pyrido-or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
TW477787B (en)	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
US6509320B1 (en) *	1996-10-16	2003-01-21	Icn Pharmaceuticals, Inc.	Purine L-nucleosides, analogs and uses thereof
US6147080A (en)	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
GB9700226D0 (en)	1997-01-08	1997-02-26	Glaxo Group Ltd	Inhalation device
MY117948A (en)	1997-01-13	2004-08-30	Glaxo Group Ltd	Nitride oxide synthase inhibitors.
US6498163B1 (en) *	1997-02-05	2002-12-24	Warner-Lambert Company	Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
JP2001509805A (ja)	1997-02-05	2001-07-24	ワーナー−ランバート・コンパニー	細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン
US5945422A (en) *	1997-02-05	1999-08-31	Warner-Lambert Company	N-oxides of amino containing pyrido 2,3-D! pyrimidines
DE19723722A1 (de)	1997-05-30	1998-12-10	Schering Ag	Nichtsteroidale Gestagene
JP2001526230A (ja)	1997-12-19	2001-12-18	スミスクライン・ビーチャム・コーポレイション	ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
US6506766B1 (en)	1998-02-13	2003-01-14	Abbott Laboratories	Glucocortiocoid-selective antinflammatory agents
JP2002503662A (ja) *	1998-02-17	2002-02-05	テュラリクインコーポレイテッド	抗ウイルス性ピリミジン誘導体
JP2000038350A (ja)	1998-05-18	2000-02-08	Yoshitomi Pharmaceut Ind Ltd	糖尿病治療薬
US6248225B1 (en) *	1998-05-26	2001-06-19	Ppg Industries Ohio, Inc.	Process for forming a two-coat electrodeposited composite coating the composite coating and chip resistant electrodeposited coating composition
CA2329703C (en)	1998-05-26	2005-12-20	Warner-Lambert Company	Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
GB9811599D0 (en)	1998-05-30	1998-07-29	Glaxo Group Ltd	Nitric oxide synthase inhibitors
AU4429799A (en) *	1998-06-12	1999-12-30	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
US6184226B1 (en) *	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
AU761552B2 (en) *	1998-10-01	2003-06-05	Astrazeneca Ab	Chemical compounds
WO2000023444A1 (en)	1998-10-21	2000-04-27	Abbott Laboratories	5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6358959B1 (en)	1999-01-26	2002-03-19	Merck & Co., Inc.	Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
EP1175422A2 (en)	1999-05-04	2002-01-30	Ligand Pharmaceuticals Incorporated	Tetracyclic progesterone receptor modulator compounds and methods
CO5180649A1 (es)	1999-09-01	2002-07-30	Abbott Lab	Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
SK3792002A3 (en)	1999-09-17	2003-09-11	Abbott Gmbh & Co Kg	Kinase inhibitors as therapeutic agents
AU2576501A (en)	1999-12-08	2001-06-18	Advanced Medicine, Inc.	Protein kinase inhibitors
US6632666B2 (en)	2000-01-14	2003-10-14	Biolife Solutions, Inc.	Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
CN1395578A (zh)	2000-01-25	2003-02-05	沃尼尔·朗伯公司	吡啶并[2,3－d]嘧啶－2,7－二胺激酶抑制剂
WO2001055148A1 (en) *	2000-01-27	2001-08-02	Warner-Lambert Company	Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
US7235551B2 (en) *	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
KR20020075805A (ko)	2000-03-06	2002-10-05	워너-램버트 캄파니	5-알킬피리도[2,3-ｄ]피리미딘 타이로신 카이나제 억제제
AU2001283004A1 (en) *	2000-07-24	2002-02-05	Vivcom, Inc.	System and method for indexing, searching, identifying, and editing portions of electronic multimedia files
BR0114323A (pt)	2000-09-29	2003-07-01	Glaxo Group Ltd	Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto
AU2002248269A1 (en)	2000-10-19	2002-08-12	Smithkline Beecham Corporation	Use of p38 inhibitors for the treatment of inflammation-enhanced cough
CA2426654C (en) *	2000-10-23	2010-12-21	Smithkline Beecham Corporation	2,4,8-trisubstituted-8h-pyrido[2,3-d}pyrimidin-7-one compounds
CA2431904A1 (en)	2000-12-20	2002-08-01	Merck & Co., Inc.	(halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
GB0031179D0 (en)	2000-12-21	2001-01-31	Glaxo Group Ltd	Nitric oxide synthase inhibitors
US6484903B2 (en)	2001-01-09	2002-11-26	Riverwood International Corporation	Carton with an improved dispensing feature in combination with a unique handle
PE20030008A1 (es) *	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
WO2003010143A1 (en)	2001-07-26	2003-02-06	Samsung Electronics Co., Ltd.	Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses
JP4178783B2 (ja)	2001-10-19	2008-11-12	三菱化学株式会社	光学記録媒体
US7019002B2 (en) *	2001-12-11	2006-03-28	Pharmacia & Upjohn, S.P.A.	Pyridopyrimidinones derivatives as telomerase inhibitors
US6960581B2 (en)	2002-01-14	2005-11-01	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof
EP1467730A4 (en)	2002-01-22	2010-03-10	Univ California	Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof
KR20060111716A (ko) *	2002-01-22	2006-10-27	워너-램버트 캄파니 엘엘씨	2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
EP1490317A1 (en)	2002-03-26	2004-12-29	Boehringer Ingelheim Pharmaceuticals Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
KR101022977B1 (ko)	2002-03-26	2011-03-18	베링거 인겔하임 파마슈티칼즈, 인코포레이티드	글루코코르티코이드 모사체, 이의 제조방법, 약제학적조성물 및 이의 용도
DE10215316C1 (de)	2002-04-02	2003-12-18	Schering Ag	Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
WO2003086294A2 (en)	2002-04-11	2003-10-23	Merck & Co., Inc.	1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
CN1653077A (zh) *	2002-05-06	2005-08-10	健亚生物科技公司	治疗c型肝炎病毒感染的核苷衍生物
US7186864B2 (en)	2002-05-29	2007-03-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en)	2002-06-06	2006-07-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
BR0312575A (pt)	2002-07-08	2005-05-03	Pfizer Prod Inc	Moduladores do receptor de glicocorticóides
WO2004009017A2 (en)	2002-07-18	2004-01-29	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor and method
DE60331103D1 (de)	2002-07-18	2010-03-11	Bristol Myers Squibb Co	Zusammensetzungen und verfahren im zusammenhang mit der nuklearen hormon-rezeptor-stelle ii
WO2004018429A2 (en)	2002-08-21	2004-03-04	Boehringer Ingelheim Pharmaceuticals, Inc.	Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP4520309B2 (ja)	2002-09-20	2010-08-04	メルク・シャープ・エンド・ドーム・コーポレイション	選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−２−Ｈ−ナフト［１，２−ｆ］インドール−４−カルボキサミド誘導体
WO2004043367A2 (en) *	2002-11-06	2004-05-27	Bristol-Myers Squibb Company	Fused heterocyclic compounds and use thereof
JP2004203751A (ja)	2002-12-24	2004-07-22	Pfizer Inc	置換６，６−ヘテロ二環式誘導体
BRPI0406809A (pt) *	2003-01-17	2005-12-27	Warner Lambert Co	Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
MXPA05008612A (es)	2003-02-14	2005-12-05	Smithkline Beecham Corp	Compuestos novedosos.
US7138412B2 (en) *	2003-03-11	2006-11-21	Bristol-Myers Squibb Company	Tetrahydroquinoline derivatives useful as serine protease inhibitors
CA2527017A1 (en) *	2003-05-27	2004-12-09	Pfizer Products Inc.	Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
TWI220897B (en) *	2003-07-22	2004-09-11	Benq Corp	Recording media feeding system and method
WO2005014558A1 (en)	2003-08-05	2005-02-17	Vertex Pharmaceuticals Incorporated	Condensed pyramidine compounds as inhibitors of voltage-gated ion channels
US7098222B2 (en) *	2004-05-12	2006-08-29	Abbott Laboratories	Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
WO2006039469A1 (en) *	2004-09-29	2006-04-13	Graphic Packaging International, Inc	Carton with dispenser having access features
JP5111113B2 (ja) *	2004-12-13	2012-12-26	サネシスファーマシューティカルズ，インコーポレイテッド	Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
US20090137550A1 (en) *	2005-03-25	2009-05-28	Glaxo Group Limited	Novel Compounds
UY29439A1 (es) *	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
US20080096905A1 (en) *	2005-03-25	2008-04-24	Glaxo Group Limited	Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
TWI389690B (zh) *	2005-03-25	2013-03-21	Glaxo Group Ltd	新穎化合物（一）

2006
- 2006-03-23 UY UY29439A patent/UY29439A1/es unknown
- 2006-03-23 TW TW095109982A patent/TW200724142A/zh unknown
- 2006-03-23 PE PE2010000198A patent/PE20100741A1/es not_active Application Discontinuation
- 2006-03-23 PE PE2006000331A patent/PE20061193A1/es not_active Application Discontinuation
- 2006-03-23 AR ARP060101148A patent/AR053450A1/es not_active Application Discontinuation
- 2006-03-24 EP EP06748656A patent/EP1866311A4/en not_active Withdrawn
- 2006-03-24 NZ NZ561438A patent/NZ561438A/en not_active IP Right Cessation
- 2006-03-24 US US11/908,435 patent/US20090239846A1/en not_active Abandoned
- 2006-03-24 CN CN2006800183985A patent/CN101184758B/zh not_active Expired - Fee Related
- 2006-03-24 BR BRPI0609579-8A patent/BRPI0609579A2/pt not_active IP Right Cessation
- 2006-03-24 EA EA200702074A patent/EA200702074A1/ru unknown
- 2006-03-24 KR KR1020077024433A patent/KR20080005223A/ko not_active Application Discontinuation
- 2006-03-24 MX MX2007011883A patent/MX2007011883A/es active IP Right Grant
- 2006-03-24 JP JP2008503226A patent/JP2008535820A/ja active Pending
- 2006-03-24 US US11/389,112 patent/US7674789B2/en not_active Expired - Fee Related
- 2006-03-24 AU AU2006229967A patent/AU2006229967B2/en not_active Ceased
- 2006-03-24 WO PCT/US2006/010792 patent/WO2006104889A2/en active Application Filing
- 2006-03-24 SG SG201006926-8A patent/SG166100A1/en unknown
- 2006-03-24 CA CA002602546A patent/CA2602546A1/en not_active Abandoned
- 2006-03-24 AP AP2007004171A patent/AP2281A/xx active
- 2006-03-24 UA UAA200710644A patent/UA95230C2/ru unknown
2007
- 2007-09-11 IL IL185915A patent/IL185915A0/en unknown
- 2007-09-12 ZA ZA200707798A patent/ZA200707798B/xx unknown
- 2007-09-24 MA MA30236A patent/MA29340B1/fr unknown
- 2007-10-15 NO NO20075273A patent/NO20075273L/no not_active Application Discontinuation
2009
- 2009-11-16 US US12/618,927 patent/US20100093765A1/en not_active Abandoned
- 2009-11-16 US US12/618,933 patent/US20100093766A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PE20100741A1 (es)	2010-11-25
AU2006229967A1 (en)	2006-10-05
US7674789B2 (en)	2010-03-09
JP2008535820A (ja)	2008-09-04
UA95230C2 (ru)	2011-07-25
KR20080005223A (ko)	2008-01-10
AR053450A1 (es)	2007-05-09
US20100093766A1 (en)	2010-04-15
MA29340B1 (fr)	2008-03-03
WO2006104889A3 (en)	2007-04-12
AP2007004171A0 (en)	2007-10-31
IL185915A0 (en)	2008-01-06
EP1866311A2 (en)	2007-12-19
US20090239846A1 (en)	2009-09-24
MX2007011883A (es)	2007-11-13
AP2281A (en)	2011-10-31
ZA200707798B (en)	2009-08-26
SG166100A1 (en)	2010-11-29
EA200702074A1 (ru)	2008-02-28
US20100093765A1 (en)	2010-04-15
WO2006104889A2 (en)	2006-10-05
PE20061193A1 (es)	2006-12-02
BRPI0609579A2 (pt)	2010-04-20
UY29439A1 (es)	2006-10-02
AU2006229967B2 (en)	2012-02-09
NZ561438A (en)	2011-02-25
EP1866311A4 (en)	2010-03-31
CN101184758B (zh)	2012-05-02
NO20075273L (no)	2007-12-12
CN101184758A (zh)	2008-05-21
CA2602546A1 (en)	2006-10-05
US20060235030A1 (en)	2006-10-19

Publication	Publication Date	Title
TW200724142A (en)	2007-07-01	Novel compounds
MY145343A (en)	2012-01-31	Novel compounds
WO2007147109A3 (en)	2008-11-13	Novel compounds
WO2007147103A3 (en)	2008-11-13	Novel compounds
CA2603830A1 (en)	2006-11-30	PYRIDINE [2,3-B] PYRAZINONES
ZA201004368B (en)	2013-01-30	Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
MX2009010728A (es)	2009-10-26	Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
MY169791A (en)	2019-05-15	Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
IL195238A0 (en)	2009-08-03	Pyrazolo [1,5-a]pyrimidines as cdk inhibitors
IL210071A0 (en)	2011-02-28	Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
WO2004021979A3 (en)	2004-09-30	PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
TNSN07440A1 (en)	2009-03-17	Derivatives of pyrido [2,3 -d] pyrimidine, the preparation thereof, and the therapeutic application of the same
IL164606A0 (en)	2005-12-18	Novel compounds
AP2008004437A0 (en)	2008-04-30	Pyrazolo Ä4,3-DÜ pyrimidin-5-yl) derivative used as PDE5 inhibitors
WO2006033795A3 (en)	2006-08-10	Substituted pyrazolo [1, 5-a] pyrimidines for inhibiting abnormal cell growth
TW200738721A (en)	2007-10-16	7-Amino-6-heteroaryl-1,2,4-triazolo[1,5-a]pyrimidine compounds and their use for controlling harmful fungi
WO2007147104A3 (en)	2008-10-30	Novel compounds
DK2059521T3 (da)	2010-09-27	Pyrazolo[1,5-A]pyrimidiner, fremgangsmåder, anvendelse og sammensætninger
TW200745115A (en)	2007-12-16	7-Amino-6-heteroaryl-1,2,4-triazolo[1,5-a]pyrimidine compounds and their use for controlling harmful fungi
IL181900A0 (en)	2007-07-04	7-aminomethyl-1,2,4-triazolo[1,5-a] pyrimidine compounds and their use for controlling pathogenic fungi
TW200738720A (en)	2007-10-16	7-Amino-6-heteroaryl-1,2,4-triazolo[1,5-a]pyrimidine compounds and their use for controlling harmful fungi
TW200635928A (en)	2006-10-16	7-Amino-6-heteroaryl-1,2,4-triazolo[1,5-a]pyrimidine and the use thereof for controlling harmful fungi
CL2008001974A1 (es)	2009-06-05	Compuestos derivados de ciclopenta[d]pirimidina inhibidores de la quinasa akt; proceso de preparacion; kit farmaceutico; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, hiperproliferativas, cardiovasculares, neurode genarativas, entre otras.